Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.50 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.48 |
| ▸ | FEN1 | P39748 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27936838 | 1.00 | ABHD6 (0.50) | ABHD6DAGLAKDM1AALOX5APFEN1 | |
| SCHEMBL938055 | 1.00 | ABHD6 (0.50) | ABHD6DAGLAKDM1AALOX5APFEN1 | |
| SCHEMBL4324219 | 0.96 | LTA4H (0.48) | ABHD6DAGLAKDM1AALOX5APGPR119 | |
| SCHEMBL4324225 | 0.96 | LTA4H (0.48) | ABHD6DAGLAKDM1AALOX5APGPR119 | |
| SCHEMBL4319616 | 0.91 | ALOX5AP (0.50) | ALOX5APFEN1GPR119CHRNB2CHRNA4 | |
| SCHEMBL4318335 | 0.91 | GPR119 (0.49) | ALOX5APFEN1GPR119CHRNB4CHRNA3 | |
| SCHEMBL4317028 | 0.91 | ALOX5AP (0.50) | ALOX5APFEN1GPR119CHRNB2CHRNA4 | |
| SCHEMBL4318329 | 0.91 | GPR119 (0.49) | ALOX5APFEN1GPR119CHRNB4CHRNA3 | |
| SCHEMBL4314700 | 0.91 | PRMT5 (0.56) | ALOX5APCHRNB2CHRNA4 | |
| SCHEMBL4314170 | 0.91 | PRMT5 (0.56) | ALOX5APCHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2283004-B1 | AMIDO-THIOPHENE COMPOUNDS AND THEIR USE | UNIV EDINBURGH (GB) | 2015-05-27 | — | — | EP | disclosed |
| EP-2283004-B1 | AMIDO-THIOPHENE COMPOUNDS AND THEIR USE | UNIV EDINBURGH (GB) | 2015-05-27 | — | — | EP | disclosed |
| US-8614209-B2 | Amido-thiophene compounds and their use | THE UNIVERSITY OF EDINBURGH (GB) | 2013-12-24 | — | — | US | disclosed |
| US-20130012545-A1 | Amido-Thiophene Compounds and Their Use | THE UNIVERSITY OF EDINBURGH (GB) | 2013-01-10 | — | — | US | disclosed |
| US-20130012545-A1 | Amido-Thiophene Compounds and Their Use | THE UNIVERSITY OF EDINBURGH (GB) | 2013-01-10 | — | — | US | disclosed |
| US-20130012545-A1 | Amido-Thiophene Compounds and Their Use | THE UNIVERSITY OF EDINBURGH (GB) | 2013-01-10 | — | — | US | disclosed |
| US-8329686-B2 | Isatin analogues and uses therefor | WASHINGTON UNIVERSITY (US) | 2012-12-11 | — | — | US | disclosed |
| US-8299063-B2 | Amido-thiophene compounds and their use | THE UNIVERSITY OF EDINBURGH (GB) | 2012-10-30 | — | — | US | disclosed |
| US-8299063-B2 | Amido-thiophene compounds and their use | THE UNIVERSITY OF EDINBURGH (GB) | 2012-10-30 | — | — | US | disclosed |
| US-8299063-B2 | Amido-thiophene compounds and their use | THE UNIVERSITY OF EDINBURGH (GB) | 2012-10-30 | — | — | US | disclosed |
| EP-1242081-A1 | CASPASES AND APOPTOSIS | SmithKline Beecham Corporation (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6403792-B1 | INHIBIT PRODUCTION OF CASPASE 3 AND 7 IN MAMMALS | SMITHKLINE BEECHAM CORPORATION | 2002-06-11 | — | — | US | disclosed |
| US-6277871-B1 | ANTICANCER AGENTS | ABBOTT LABORATORIES | 2001-08-21 | — | — | US | disclosed |
| US-6221865-B1 | INHIBITORS OF PROTEIN FARNESYLTRANSFERASE AND PROTEIN GERANYLGERANYLTRANSFERASE. | UNIVERSITY OF PITTSBURGH | 2001-04-24 | — | — | US | disclosed |
| WO-2001022966-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-1087663-A2 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-1001933-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999065451-A2 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999006367-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
| US-5472958-A | 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function | ABBOTT LABORATORIES (US) | 1995-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012545-A1 | Amido-Thiophene Compounds and Their Use | HSD11B1, HSD11B2, HSD17B1 | ABHD6 537/4885DAGLA 1473/4885KDM1A 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.